Fibrinolysis-enhancing agents

Details Fibrinolysis-enhancing agents Fibrinolysis-enhancing agents

A - Human Necessities

61

K

167/225, 167/258

A61K 31/635 (2006.01) A61K 31/18 (2006.01) A61K 31/445 (2006.01) A61K 31/47 (2006.01) A61K 31/63 (2006.01) A61K 38/49 (2006.01)

Patent

CA 1269617

FIBRINOLYSIS-ENHANCING AGENTS ABSTRACT OF THE DISCLOSURE Disclosed herein is a fibrinolysis-enhancing agent comprising, as an effective ingredient, an N2-arylsulfonyl- L-arginine amide represented by the general formula (I): Image ... ... (I) wherein R1 is a group of the formula: Image where R3 is an alkyl group having 3 to 5 carbon atoms or an alkoxyalkyl group having 2 to 4 carbon atoms and R4 is an alkyl group having 1 to 3 carbon atoms; and R2 is a group of the formula: Image where R5 and R6 are independently hydrogen atom, methyl group or methoxy group provided that they cannot be hydrogen atoms simultaneously, and R7 is an alkyl group having 1 to 3 carbon atoms; or a salt thereof. The agent is used in combination with a plasminogen activator.

494713

Affiliated with

Also associated with

Rating

Fibrinolysis-enhancing agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fibrinolysis-enhancing agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fibrinolysis-enhancing agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1205577